The case for & against
Bull & Bear analysis
Bearish
Becton, Dickinson and Company (NYSE: BDX) is a leading global medical technology company specializing in the development and manufacturing of a wide array of medical devices, instrumentation, and reagents. BD operates in a competitive healthcare market, addressing needs across various segments, including Medication Delivery Solutions, Biosciences, and BD Interventional. The company is well-positioned within the healthcare supply chain, offering innovative solutions aimed at enhancing patient care while navigating market dynamics and evolving regulations.
Bull says
- ↑Maintains 3.6% dividend yield, returning $2.3B to shareholders in H1
- ↑Q2 revenue rose 2.6% YoY to $4.7B, led by double-digit biologics growth
- ↑Executed $2B in share repurchases, demonstrating disciplined capital allocation
- ↑Adjusted EPS climbed 3.9% YoY to $2.90, while operating margin held near 24.2%
- ↑Investing in R&D for biologics and advanced monitoring; Pixis Pro shows early traction
- ↑High dividend yield and positive earnings yield support attractive valuation
Bear says
- ↓Profitability and growth factors are weak, raising earnings sustainability concerns
- ↓FDA warning letter on compliance poses reputational and revenue risks
- ↓Significant vaccine demand decline may reduce recurring revenues
- ↓High short interest and negative earnings revisions reflect market skepticism
- ↓Tariff-driven costs compressed operating margin by 110bps to 24.2%
- ↓Value-based procurement policies in China threaten future sales
Investment themes with BDX
High Dividend Yield↑ +0.32%
Companies paying above-average dividends
AVGO · JPM · XOM
Medical Devices↑ +0.12%
Devices and instruments for medical treatment
ISRG · ABT · SYK
Earnings Call · Q2 2026 · Mgmt. Guidance
Updated 05-10-2026neutral
Transcript signals
Bull points
- Oral GOP1 is expected to be incremental and complementary. It's great to see the progress on that and how it's helping so many people around the world.
- GLP-1s, they remain a strong growth driver for us and a big focus. As we said, we actually announced on this call two new significant deals with large pharmaceutical companies for new novel GLP-1 molecules, and that continues to be a focus of ours is ensuring those come into our devices.
- over 80 GLP-1 biosimilar deals signed to be in our devices, and those are not just in our syringes. but they also could be deals that we've signed with our auto injectors or with our pens, which come at higher ASPs, several times higher ASP than when we just sell a syringe, which is really what we're selling today in GLP-1.
Bear points
- China is going to continue to become a smaller portion of our revenue, around 4% of new BD today. And we'll probably drop below that just as the rest of the portfolio grows as we go into 27, perhaps into the threes.
- we have 100 basis points of Alaris headwind this year. We've been very clear that that will move to 200 basis points of headwind next year, and just as we've completed the remediation this year, and then that will stabilize.
- there's been a significant drop in vaccine demand. You see that across essentially every pharma company that's in the vaccine space and in companies that are supplying devices for their use, of which we're by far the market leader in.
Read full transcript analysis ›